NCT00035178View on ClinicalTrials.gov

Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

November 30, 2002

Conditions

Kidney Failure, ChronicRenal Disease, End-Stage

Interventions

DRUG

Argatroban

Trial Locations (2)

55404

DaVita Clinical Research, Minneapolis

60637

University of Chicago, Section of Nephrology, Chicago

All Listed Sponsors

lead

Texas Biotechnology Corporation

INDUSTRY

NCT00035178 - Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis | Biotech Hunter | Biotech Hunter